HMGB1 and type 2 diabetes mellitus: A study indicated that, in comparison to the control group receiving insulin, the levels of interleukin-1 beta, monocyte chemoattractant protein-1, and HMGB1 significantly decreased in T2D patients receiving interventions combined with QRLSD.